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Abstract
Objectives The population of adults with congenital heart defects (ACHD) is continuously growing. Data on morbidity and
mortality of ACHD are limited. This longitudinal observational study examined a group of ACHD with surgically corrected
or palliated congenital heart defects (CHD) during a 15-year period.
Methods ACHD that had participated in the initial study were invited for a follow-up examination. Mortality and hospitalization data were compared with a healthy control group.
Results From 05/2017 to 04/2019 a total of 249/364 (68%) ACHD participated in the follow-up study: 21% had mild, 60%
moderate and 19% severe CHD. During the observational period, 290 health incidents occurred (cardiac catheterization 37%,
cardiovascular surgery 27%, electrophysiological study/ablation 20%, catheter interventional treatment 14%, non-cardiac
surgery 3%). Events were more frequent in ACHD with moderate (53%) and severe (87%) compared to those with mild CHD
(p < 0.001). 24 individuals died at a median age of 43 years during the observation period. 29% of them had moderate and
71% severe CHD corresponding to a mortality rate of 0%, 0.29% and 1.68% per patient-year in ACHD with mild, moderate
and severe CHD. Long-term survival was significantly reduced in patients with severe CHD in comparison to individuals
with mild and moderate CHD (p < 0.001).
Conclusion After correction or palliation of CHD, there was remarkable ongoing morbidity and mortality in ACHD patients
over the 15-year observation period, particularly in individuals with moderate and severe CHD when compared with the
general population. Thus, life-long special care is required for all surgically corrected or palliated ACHD patients.
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Abbreviations
ACHD	Adults with congenital heart defect
AR	Aortic regurgitation
AS	Aortic stenosis (valvulär/subvalvulär/
supravalvulär)
ASD	Atrial septal defect
CHD	Congenital heart defect
ccTGA	Congenitally corrected transposition of the great
arteries
dTGA	Dextroposition transposition of the great arteries
DILV	Double inlet left ventricle
DORV	Double outlet right ventricle
EPS	Electrophysiological study
F	Female
Fig.	Figure
HR	Hazard ratio
IQR	Interquartile range
LC	Life chances
M	Male
n.s	Not significant
Py	Patient years
PA	Pulmonary atresia
SOEP	German Socio-Economic Panel
TOF	Tetralogy of Fallot
TA	Tricuspid atresia
VF	Ventricular fibrillation
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VSD	Ventricular septal defect
VT	Ventricular tachycardia

Introduction
About 1% of all live births suffer from a malformation
of the heart or great vessels. Thanks to advances in diagnostics and treatment, more than 90% of children with
the whole spectrum of congenital heart defects (CHD) are
reaching adulthood now. Thus, the population of adults
with congenital heart defects (ACHD) is continuously
increasing and aging [1]. In general, ACHD represents
a relatively new patient population with a broad variety
of CHD from mild to severe [2]. Regardless of severity,
almost all patients with CHD suffer from chronic heart
disease, which requires regular follow-up care by CHDspecialized cardiologists. Particular attention must be paid
to potential residuals of corrected or palliated CHD and
additional comorbidities [3]. The present longitudinal
observational study was designed to examine the longterm course of patients with surgically corrected or palliated heart defects over a period of 15 years in a tertiary
ACHD facility by examining the morbidity and mortality
in comparison with controls from the general population.

Clinical Research in Cardiology

Patients and methods
In a previous cross-sectional study in our center from 2003
to 2004 (reviewed and approved by the ethics committee
of Hannover Medical School under no. 3710, date: 04-102004 and by the University Clinic of Goettingen under no.
10/2/01, date: 01-03-2001) entitled Life Chances 1 (LC1), a
total of 364 patients with various types of corrected or palliated CHD had been extensively studied [4, 5]. These patients
had a median age of 24 (range 14 to 45) years. For the current study, Life Chances 2 (LC2), all 364 patients from LC1
were contacted by phone, via mail, or via their general practitioners (Fig. 1). Between 05/2017 and 04/2019, all patients
were invited to our outpatient clinic for follow-up examination that included medical history, physical examination,
ECG, 2D- and 3D-echocardiogram, blood sampling, exercise stress testing, and socio-medical interview (reviewed
and approved by the ethics committee of the University of
Goettingen, no. 15/8/14). Complexity of CHD was defined
as mild, moderate, and severe according to the 2020 ESC
Guidelines for the management of adult congenital heart
disease [1]. In patients with multiple cardiac lesions, the
lesion of highest complexity was assigned.
To evaluate the findings on morbidity and mortality in the
patient sample, control groups were drawn from the German
Socio-Economic Panel (SOEP) as a national longitudinal
German population survey. Controls for comparing morbidity were drawn from the survey 2004 by using age, gender,
and parental education as matching variables. Parental education was used as a replacement for own education as many
patients had not completed school education when the first

survey was conducted. Finally, 363 cases with longitudinal
records were drawn. For mortality, 1089 controls were available as also shorter observation periods could be allowed for.

Patient and public involvement
Patients were not involved in planning and realization of
this project. During the initial cross-sectional study from
2003 to 2004, patients with various types of corrected or
palliated CHD were consecutively recruited during visits
from the outpatient clinic of the Department of Pediatric
Cardiology and Intensive Care Medicine, Georg August
University Medical Center, Goettingen, Germany. Between
05/2017 and 04/2019, all patients were invited to the outpatient clinic for follow-up examinations. After the first and
the second study, findings were presented and discussed in
a symposium for patients.

Statistics
Statistical analyses were performed using SPSS® 26.0
(IBM, New York, USA). Numerical data are presented as
median and interquartile range (IQR). Differences between
numerical data were calculated using non-parametric
tests, Mann–Whitney-U test, or Kruskal–Wallis test. Differences between variables were calculated by Chi-square
test. Patient-years (py) were calculated as total years
between inclusion into LC1 and LC2 or, if deceased, until
date of death. For patients with an unknown date of death,
05/31/2017 was inferred as the date of death which was the
start of LC2. Mortality was calculated by dividing the number of deaths by total patient-years between LC1 and LC2.
Long-term survival is displayed by Kaplan–Meier survival
curves and was tested for significance by the log-rank test.
Risk for death was calculated by Cox regression analysis
and described as hazard ratio (HR). A p value < 0.05 was
defined as error level.

Results
Study population

Fig. 1  Flowchart of patients who participated in LC2 (LC: Life
Chances)

Of the 364 individuals of LC1, a total of 221 patients (61%)
followed the invitation for the follow-up examination for
LC2 (Fig. 1). Another 28/364 (8%) patients completed a
socio-medical questionnaire only, resulting in a total attendance of 249/364 patients (68%) at a median age of 38 (IQR:
33–47) years, while the youngest patient was 27 and the
oldest was 60 years of age, respectively.
The remaining 115/364 (32%) patients did not participate
in LC2. The reasons included:
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1. The patient could not be reached/was lost to follow-up
(48/364; 13%).
2. 45/364 (12%) patients refused to participate in LC2.
Of those, 20% had a simple, 47% a moderate and 33%
a severe CHD, respectively. 14/45 (31%) patients had
been studied in LC1 and had not further regular cardiac checkups thereafter. The remaining 69% (31/45)
attended regular cardiac checkup at our tertiary ACHD
facility, but could not be motivated to participate in LC2.
3. The patient had died (22/364; 6%). Two others died
shortly after inclusion in LC2, totaling 24 deaths. All
patients who could be contacted but refused to participate in LC2 were assigned the status "alive" at the time
of LC2 (Fig. 1).

Follow‑up visits from LC1 to LC2
Two patient questionnaire surveys were conducted. Initially,
patients were asked during data collection for LC1 and subsequently during data collection for LC2.
For clinical examination, there were no exactly defined
periods of follow-up visits between LC1 and LC2. 63%
of LC2 study patients had presented to regular cardiology
examinations, i.e., at least once every 5 years. The remaining
37% had not undergone regular cardiac follow-up assessment (p < 0.05). The severity of CHD had an impact on
regular cardiologic follow-up visits: 35% with mild CHD

had regular follow-up visits vs. 64% with moderate and 89%
with severe CHD.

Cardiac malformations
For detailed analyses of LC1 and LC2, all cardiac malformations present in more than 14 individuals in LC1 were
grouped as a specific entity. Rare cardiac defects involving
less than 14 patients were classified as "others". All patients
with univentricular hearts who had any type of a Fontan
Circulation were assigned to “Fontan Circulation” irrespective of the specific underlying cardiac malformation. In this
way, all patients could be assigned to ten different diagnosis
groups (Fig. 2). Detailed basic information from all patients
of LC1 and LC2 are displayed in Table 1.

Severity of CHD
Distribution of CHD severity among participants of LC1 and
LC2 did not differ significantly. Severity of CHD of the 364
patients (female n = 154, 42%) of LC1 was as follows: mild
in 81 patients (22%), moderate in 199 (55%) and severe in
84 (23%). Of the 249 patients in LC2 (female n = 105, 42%),
52 patients (21%) had mild, 150 (60%) had moderate and 47
(19%) had severe CHD (n.s.).
In contrast, distribution of CHD severity was significantly different in patients who were lost to follow-up

Fig. 2  Vertical bar charts show the number of patients per diagnosis group at LC1 (left bar chart) and, at LC2 (right bar chart)
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Table 1  Detailed patient characteristics according to the ten diagnosis groups at LC1 and LC2
Congenital heart defect (n; %)

LC I
LC II
LC I
LC II
LC I
LC II

LC I
LC II
LC I
LC II
LC I
LC II

LC I
LC II
LC I
LC II
LC 1
LC II
LC I
LC II

Aortic valve and sinus valsalva disease
37/364; 10%
27/249; 11%
ASD
24/364; 7%
15/249; 6%
Atrioventricular canal defect (partial/complete)
15/364; 4%
12/249; 5%
Dextroposition transposition of the great arteries except
atrial switch operation
33/364; 9%
19/249; 8%
Fontan Circulation
17/364; 5%
9/249;4%
Interrupted/stenotic aortic arch
48/364; 13%
38/249; 15%
Pulomonary artery stenosis (valvular/subvalvular/supravalvular)
18/364; 5%
14/249; 6%
Tetralogy of Fallot
72/364; 20%
51/249; 20%
Ventricular septal defect
34/364; 9%
21/249; 8%
Others
66/364; 18%
43/249; 17%

(n = 48) compared to patients of LC2. Patients who were
lost to follow-up had significantly more often mild than
moderate and severe CHD, respectively (p = 0.001).
In general, the inclusion rate between LC1 and LC2
decreased for each CHD group by approximately 20–30%.
It is of note, that the highest non-responder rates were present in the groups of patients with dextroposition transposition of the great arteries (dTGA, 14/33; 42%) and Fontan
Circulation (8/17; 47%). 5/14 (36%) patients with dTGA
had died between LC1 and LC2, 3/14 (21%) could not be
reached and 6/14 (43%) did not want to participate in LC2.
Reasons for non-participation in LC2 for patients with a
Fontan circulation were death in 3/8 (38%), lost to followup in 1/8 (13%) or refusal to participate in 4/8 (50%).

Gender
Age in years
Female (n; %) (median;
range)

p value

Body mass
index (median;
range)

p value

8 (22%)
4 (15%)

27.0; 14.0–43.0
23.7; 16.9–38.0
41.0; 28.0–58.0 p < 0.001 25.2; 19.1–49.6

p = 0.01

14 (58%)
9 (60%)

19.5; 14.0–42.0
23.1; 16.0–37.6
35.0; 27.0–56.0 p < 0.001 23.7; 19.0–33.5

p < 0.023

8 (53%)
7 (58%)

23.0; 15.0–39.0
22.1; 17.4–34.2
39.5; 29.0–52.0 p < 0.001 24.1; 19.9–36.1

p = 0.003

7 (21%)
4 (21%)

22.0; 16.0–42.0
22.2; 16.6–34.8
35.0; 30.0–49.0 p < 0.001 25.7; 18.1–33.6

p = 0.002

9 (53%)
5 (56%)

29.0; 14.0–39.0
22.1; 17.6–34.2
37.0; 29.0–52.0 p < 0.001 22.4; 20.8–33.3

p = 0.008

18 (38%)
16 (42%)

23.0; 14.0–42.0
23.7; 16.3–32.4
38.0; 28.0–56.0 p < 0.001 25.6; 17.0–33.7

p =  < 0.001

8 (44%)
6 (43%)

23.5; 14.0–44.0
23.6; 17.5–33.5
37.0 28.0–58.0 p < 0.001 26.3; 17.0–45.4

p = 0.027

34 (47%)
22 (43%)

32.0; 15.0–44.0
23.6; 16.9–31.5
47.0; 29.0–59.0 p < 0.001 24.9; 20.7–41.0

p =  < 0.001

13 (38%)
9 (43%)

21.0; 14.0–45.0
23.5; 18.9–34.7
36.0; 28.0–60.0 p < 0.001 25.7; 19.0–45.0

p = 0.016

35 (53%)
23 (54%)

23.5; 14.0–44.0
22.7; 16.3–35.3
35.0; 27.0–58.0 p < 0.001 25.1 16.0–39.7

p = 0.002

Hospitalizations
Hospitalization records were available from 234 individuals who participated in LC2. Of those, 147 (63%) needed
hospitalization during follow-up. 127/147 (86%) ACHD
patients were admitted to the hospital for cardiac reasons.
Annual hospitalization rates increased with severity of
CHD (Fig. 3). Compared to 238 healthy controls matched
for age, sex and education, hospitalization rates were significantly higher for patients with CHD than for controls
(p = 0.008). However, this finding was mainly related to
patients with severe CHD (Fig. 3).
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Fig. 3  Hospitalizations per year
(mean ± SD) of patients with
mild, moderate and severe CHD
and healthy individuals

Morbidity

Mortality

A total of 290 interventions were performed between LC1
and LC2 including cardiac catheterization (n = 106/290;
37%), cardiovascular surgery (n = 79/290; 27%), electrophysiological study (EPS) and/or catheter ablation (n = 57/290; 20%), interventional catheterization
(n = 39/290; 13%) and non-cardiac surgery (n = 9/290;
3%). Interventions were more frequent in patients with
moderate CHD (78/146 patients, 53%) and severe CHD
(41/47 patients, 87%) than in individuals with mild CHD
(15/48 patients, 31%; p < 0.001). Importantly, this effect
was not influenced by age, as there was no age difference between individuals with mild (median age 36.0;
IQR 33.0–43.3 years), moderate (median age 40.0; IQR
33.8–48.0) and severe CHD (median age 35.0; IQR
33.0–43.0 years; p = n.s. for each group tested against
each other).

For assessment of mortality, all patients who were not
available at LC2 (n = 48) were excluded from further analysis. Thus, survival status at LC2 was known from 316/364
(87%) patients. During the follow-up period between LC1
and LC2 covering a total of 4.285 patient-years, 24/316
patients had died (8%) yielding a total mortality rate of
0.56%/patient-year. In patients with severe CHD, longtime survival was significantly impaired when compared
to patients with mild and moderate CHD (p < 0.001;
Fig. 4). Patients had died at a median age of 43 (IQR:
38–49) years. Causes of death were known in 14/24 (58%)
patients, of which 71% were related to CHD (Table 2).
None of the deceased patients had mild CHD, while 7
(29%) had moderate and 17 patients (71%) had severe
CHD. Women and men were equally distributed among
the deceased individuals. Figures revealed a mortality

Fig. 4  Survival from LC1 to
LC2
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Table 2  Details of the congenital heart defect, the cause of death (if known) and the patient's age at the time of death
No

CHD

Sex

Causes of death

Age at death (year)

1
2
3
4
5
6
7
8
9
10
11
12
13
14

AS
AS
ccTGA
ccTGA
DILV, Fontan
DORV
DORV
dTGA, Mustard
dTGA, Mustard
dTGA, Mustard
dTGA, Mustard
dTGA, Rastelli
HCM
M. Ebstein, Fontan

M
M
M
M
F
F
M
M
M
F
M
M
M
F

36
45
46
Unknown
28
Unknown
Unknown
51
Unknown
28
Unknown
47
39
48

15
16
17
18
19
20
21
22
23
24

Morbus Ebstein
PA, Fontan
PA, Fontan
PA, Fontan
PA, Fontan
TA, Fontan
TA, Hemifontan
TOF
TOF
TOF

F
M
F
F
M
M
F
F
f
f

Unknown
Unknown
< 90 days after heart transplantation with complicated course
Unknown
Failing Fontan
Unknown
Unknown
Liver carcinoma
Unknown
Unknown
Unknown
Decompensated heart failure
Decompensated heart failure
Pulmonary aspergillosis due to immunosuppression after heart transplantation 14 months ago
Decompensated heart failure with multiorgan failure
VT/VF
Renal failure
unknown
unknown
Failing Fontan and heart transplantation 2 days ago
< 90 days after heart transplantation with complicated course
Endocarditis
Metastatic colon carcinoma
Aspiration

rate of 0% in the mild, 0.29% in the moderate, and 1.68%
in the severe CHD group per patient-year, respectively.
When compared to patients with mild and moderate
CHD, patients with severe CHD had a nearly eightfold
higher risk of death (HR 7.97, IQR 1.12–56.62, p = 0.038)
than patients with mild CHD and a sixfold higher risk
of decease (HR 6.25, IQR 2.58 to 15.13, p < 0.001) than
individuals with moderate CHD, respectively. The highest
mortality rate occured in patients with Fontan Circulation (19%, 1.4%/patient-year) followed by patients with
dTGA after atrial switch operation (16%, 1.3%/patientyear; see Table 3). When compared to healthy controls
matched for age, sex, and education, patients with CHD
had a 16-fold increase in mortality during the study period.
During the same time, 5/1089 (0.46%) healthy individuals had died reflecting a mortality of 0.035% per personyear (p < 0.0001). In healthy controls, mortality ranged
between 0 and 1% per 5-year-age group for all ages including those individuals who had already been in the “higher”
age groups above 31 years at LC1 (Fig. 5). In contrast,
patients with CHD had a significantly increased mortality compared to their age-matched healty controls for all
age groups (p < 0.05 per age group). This finding emerged

40
39
42
unknown
39
44
54
53
50
31

Table 3  Annual mortality risk (%) according to the diagnosis groups
Patient group with cases of death

Mortality risk per
patient-year (%)

Aortic valve and sinus Valsalva disease
Tetralogy of Fallot
Others
Dextroposition transposition of the great arteries
except atrial switch operation
Fontan circulation
Total
Healthy individuals

0.43
0.85
0.87
1.3
1.4
0.56
0.035

irrespective of younger or older age at the beginning of the
study, revealing the greatest difference for those individuals above 31 years (Fig. 5).

Socio‑medical interview
Data on the socio-medical interview were collected and
analyzed by the Medical Sociology Unit, Hannover Medical
School. A focus was placed on "Life chances after surgery
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Fig. 5  Death in controls (blue
line) to study population with
CHD (red line). Age at LC1 was
used as the baseline for statistical analysis. There was a significant difference in death between
controls and CHD patients in
each age group (p ≤ 0.012)

of congenital heart disease". The educational and occupational performance of patients over the 15 years period was
examined. Patient data were compared with a control group
generated from the German Socio-Economic Panel (SOEP),
which included subjects from the first survey (2003–2004)
and who were already included in LC2. Our patients, when
compared with the control group, did not exibit any differences in intergenerational educational mobility. When compared for the intragenerational social mobility, however,
there were more frequent downward changes [6].

Discussion
This longitudinal observational study provides long-term
data of an ACHD population—in the middle of their life
from a single tertiary ACHD center revealing high morbidity
and mortality compared to age-matched healthy controls. Of
particular importance is the fact, that patients studied were
not limited to a singular entitiy of CHD, but represented the
entire spectrum from mild to severe CHD.
Due to advances in diagnostics, interventions, surgery,
and care for ACHD in the last decades, the number of ACHD
reaching adulthood has steadily increased [7]. In childhood
survivors of CHD, the mortality rate has declined by a comparable amount to the general public [8]. These fortunate
findings are particularly applicable in patients with mild
CHD who have shown comparable [9] or only slightly elevated mortality rates [10, 11] when compared to the general
population as found in our study. None of the patients with
mild CHD had died during the study period, while we were
able to focus on a significantly longer follow-up period than
previous studied [2]. It is of note, however, that we included
fewer patients with mild CHD (21%) compared to previous
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reports and to what is expected in the overall ACHD population (55%) [7]. Our data reflect the pattern of care of ACHD
patients in a large tertiary ACHD facility covering more
patients with moderate and severe cardiac malformations.
As reported before [9, 12], our patients with moderate and
particularly severe CHD exhibited an increased mortality
during the follow-up period. This finding is significant as
our patients had already been “long-term survivors”, i.e.,
survivors of childhood, when they had entered into LC1.
Taking the potential study population at LC1 as a point
of departure [13], 5% had died, and another 16% did not
respond. Considering all patients of this study, mortality
correlated strongly with severity of underlying CHD. Altogether, ACHD patients of the present study had a 16-fold
higher mortality rate than expected for age-matched healthy
controls. Moreover, patients with severe CHD had a significantly increased risk of death than patients with mild and
moderate CHD.
Currently, long-term survival for patients with univentricular circulation palliated by the contemporary modifications of the Fontan procedure improved to a predicted
30-year survival of approximately 85% and without a sudden decline in survival or increase in mortality so far [14].
Almost 90% (15/17) of our patients with a Fontan Circulation had been palliated before 1995, while the earliest procedure had been performed in December 1970. These patients
had a median age of 29 years at LC1 and developed a
remarkably high mortality rate of 14% per 10 years. Almost
equally, a high mortality rate was also obserevd in patients
with dTGA after atrial switch procedures. It is known that
childhood survivors after atrial switch operation have a relatively stable period in their second and third decade of life
with accelerated morbidity and mortality rate thereafter [15].
For example, in 91 consecutive patients who had a Mustard
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repair before 1980, Cuypers et al. calculated a cumulative
survival of 84% after 10 years, 80% after 20 years, 77%
after 30 years, and 68% after 39 years, respectively [16].
Data reflect a mortality rate of 0.3% per year for patients in
their 20s and 1% per year in their 30s. At the start of LC1,
nearly 90% of our dTGA patients were < 30 years of age and
only one had been operated after 1988. Yet, in their 20s,
these patients had a high mortality rate (13%) during the
following decade. Slightly lower than patients with Fontan
Circulation or dTGA after atrial switch procedure, the mortality rate of TOF patients was 8.5% for 10 years. This was
comparable to TOF patients as reported by Cuypers et al.
during their third and fourth decade of life [17]. Altogether,
71% of our deceased ACHD patients had a cardiovascular
cause of death.
As expected, hospitalization rates were significant in our
ACHD patients. During the study period, 63% of individuals had been hospitalized while 86% of those hospitalizations were related to cardiocasvular reasons. Hospitalization rates per year were significantly increased in patients
with CHD compared to age-matched healthy controls and
were particularly high in those with severe CHD. Similarly,
a 10-year observation period from 2003 to 2012, as assessed
by the United States Nationwide Inpatient Sample Database,
found a considerable increase (up to 81.5%) in hospitalizations of ACHD patients [18], independent of the reasons for
hospitalization—treating or preventing complications and
sequelae of the CHD and of comorbidities. These numbers
reflect the increasing demands for medical care of an aging
ACHD population, yet significantly earlier than expected
from biological age [9]. Somewhat exaggeratedly expressed,
it may be speculated that CHD patients exhibit progeria.
For example, mortality of our middle-aged patients with
severe CHD corresponded to the estimated 10-year risk
for fatal cardiovascular events of the general population in
men ≥ 60 years of age or in women ≥ 70 years of age exhibiting several risk factors like high blood pressure, hypercholesterinemia and smoking according to the ESC SCORE
[19]. Whereas recent nationwide campaigns have focused
on prevention of cardiovascular risk factors to avoid early
development and late complications of cardiovascular diseases in the general population, knowledge of primary care
physicians in Germany on care of ACHD patients is low [3]
and ACHD patients do not often seek regular advice from
ACHD specialists [20, 21]. Circumstances of pre-aging,
elevated morbidity and mortality caused by cardiovascular
and non-cardiovascular reasons emphasize the need for close
and specialized surveillance of long-term ACHD survivors.
This will improve outcome and shift survival closer to the
general age-matched population, especially in patients with
moderate and severe CHD.
In summary, our study showed significantly increased
mortality in middle-aged ACHD patients with moderate and

severe CHD over a follow-up period of 15 years. Morbidity was also impressively high, as there was a high demand
for in-hospital cardiovascular interventions, particularly in
patients with severe CHD. Moving forward, prevention of
these events and timely intervention by ACHD specialists
is of paramount importance in the care of ACHD patients.

Summary and conclusions
It is a substantial finding that this longitudinal observation
study over 15 years on a well-defined cohort of ACHD confirms the findings of other studies with retrospective analysis
of multicenter registry data or single-center data on high
morbidity and mortality. It was not clear at that time, when
the study started in 2003, to what extent ACHD patients are
compromised concerning their health and life perspective.
We believe, that our data derived 15 years later are a valuable endorsement of the concept [1] that CHD is a life-long
chronic condition requiring long-term specialized care.

Limitations
The LC1 study was conducted at the Goettingen Heart
Center to assess ACHD patients in an early era of the growing ACHD population, as at this time there was a lack of
extensive data published on this topic. It was the aim of
the LC2 study to figure out how this particular and welldescribed study population fared during the 15 subsequent
years between LC1 and LC2. This longitudinal observational
design over 15 years is in contrast to retrospective analyses
of larger registries. This is the strength of the present study.
Loss of follow-up was remarkably low (13%), but may
have influenced our results, as the fate of these individuals
is unclear. However, more patients with mild CHD were lost
to follow-up than patients with severe CHD. Many factors
may have played into this, from the perceived lack of need
for follow-up visits by mild CHD patients, or more often
changes in their place of residence as more individuals with
mild CHD could not be reached after a period of 15 years.
Furthermore, 12% of patients declined to participate in LC2
(45/364). The reasons were not precisely queried during data
collection. Neither regular cardiology examinations at our
tertiary ACHD facility nor higher severity of the CHD was
a guarantee for participation in LC2. It may be speculated
that these patients lacked an interest in participating in our
repeat study or that they objected to take a closer look at
their heart disease. Data presented was influenced by the fact
that, when compared to previous studies, fewer patients with
mild CHD were included in LC1 and LC2, reflecting the care
of ACHD patients with moderate and severe CHD in a large
tertiary ACHD center. Taking the limitations of this study
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into account, it will definitely be useful to conduct studies
on ACHD patients in the future as multicenter studies on
longitudinal observational basis.

Appendix
See below Tables 4 and 5.

Table 4  STROBE Statement—checklist of items that should be included in reports of observational studies

Title and abstract

Item No Recommendation

Page no

1

(a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what
was found

1, 3, 7
3

Introduction
Background/rationale
Objectives
Methods
Study design
Setting

2
3

Explain the scientific background and rationale for the investigation being reported
State specific objectives, including any prespecified hypotheses

6
6

4
5

6
6, 7

Participants

6

Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,
follow-up, and data collection
(a) Cohort study—give the eligibility criteria, and the sources and methods of selection of
participants. Describe methods of follow-up
Case–control study—give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
Cross-sectional study—give the eligibility criteria, and the sources and methods of selection of
participants
(b) Cohort study—for matched studies, give matching criteria and number of exposed and
unexposed
Case–control study—for matched studies, give matching criteria and the number of controls
per case
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
Give diagnostic criteria, if applicable
For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Describe any efforts to address potential sources of bias
Explain how the study size was arrived at
Explain how quantitative variables were handled in the analyses. If applicable, describe which
groupings were chosen and why
(a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—if applicable, explain how loss to follow-up was addressed
Case–control study—if applicable, explain how matching of cases and controls was addressed
Cross-sectional study—if applicable, describe analytical methods taking account of sampling
strategy
(e) Describe any sensitivity analyses

Variables

7

Data sources/ measurement 8*
Bias
Study size
Quantitative variables

9
10
11

Statistical methods

12

13

6, 7

%

7
7
%
6, 7, 8
7, 8
7, 8
6, 7
%
6, 7,

%
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Table 5  Results
Participants

13* (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on
exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—summarize follow-up time (e.g., average and total amount)
Outcome data
15* Cohort study—report numbers of outcome events or summary measures over time
Case–control study—report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—report numbers of outcome events or summary measures
Main results
16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision
(e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were
included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time
period
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results
18 Summarize key results with reference to study objectives
Limitations
19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss
both direction and magnitude of any potential bias
Interpretation
20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding
22 Give the source of funding and the role of the funders for the present study and, if applicable, for the
original study on which the present article is based
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